Local Excision Safe, Effective for Stage II Rectal Cancer Local Excision Safe, Effective for Stage II Rectal Cancer
The investigation supports less invasive surgery for select patients with stage II disease. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 13, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Robotic Surgery Tops Laparoscopic Surgery for Middle and Low Rectal Cancer
(MedPage Today) -- Robotic surgery resulted in better quality of resection for patients with middle and low rectal cancer compared with conventional laparoscopic surgery, a randomized trial in China showed.
In a modified intention-to-treat analysis... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 10, 2022 Category: Gastroenterology Source Type: news
Galunisertib Added to Standard Treatment Promising in Rectal Cancer
(MedPage Today) -- Adding the investigational TGF-β type I receptor kinase inhibitor galunisertib to neoadjuvant chemoradiotherapy was associated with improved response rates in patients with locally advanced rectal cancer compared with historical... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 3, 2022 Category: Gastroenterology Source Type: news
Can Pre-Op Chemo Set Stage for Organ-Sparing Surgery in Early Rectal Cancer?
(MedPage Today) -- Three months of induction chemotherapy resulted in successful downstaging for certain patients with early-stage rectal cancer, enabling them to undergo organ-sparing therapy, according to a phase II trial.
In 33 of 58 patients... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 30, 2022 Category: Gastroenterology Source Type: news
Imaging Cuts Anastomotic Leakage in Rectal Cancer Surgery Imaging Cuts Anastomotic Leakage in Rectal Cancer Surgery
The incidence of leakage was three times lower when using indocyanine green fluorescence angiography. The study was published as a preprint and has not yet been peer reviewed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 19, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
The Multidisciplinary Management of Advanced Rectal Cancer The Multidisciplinary Management of Advanced Rectal Cancer
The complexity of locally advanced rectal cancer treatment requires a multidisciplinary approach. Learn about the shifting paradigm towards more personalized care.Journal of Oncology Practice (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 16, 2022 Category: Radiology Tags: Hematology-Oncology Journal Article Source Type: news
Eye-catching cancer drug trial results have researchers asking: What’s next?
The study pertained to a small group of rectal cancer patients whose tumors shared a specific abnormality, but the therapy could have implications for similar subsets of cancers. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - June 10, 2022 Category: Consumer Health News Authors: Kim Bellware Source Type: news
Rectal cancer: researchers hail ‘breakthrough’ experimental treatment
Every patient treated with immunotherapy drug went into remission, researchers in New York reportedEvery patient treated for rectal cancer with an experimental immunotherapy drug went into remission, in findings that researchers have hailed as a breakthrough.All 14 patients who were given the new drug, dostarlimab, were found after six months to have no trace of cancer. Researchers at Memorial Sloan Kettering cancer center in New York could find no sign of the disease through physical examination, endoscopies, MRIs or other scans.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - June 8, 2022 Category: Science Authors: Ed Pilkington in New York Tags: Cancer research Medical research Science Source Type: news
Small cancer drug trial sees tumors disappear in 100 percent of patients
A small drug trial is having a seismic impact in the world of oncology: After six months of an experimental treatment, tumors vanished in all 14 patients diagnosed with early stage rectal cancer who completed the study before its publication. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - June 8, 2022 Category: Consumer Health News Authors: Kim Bellware Source Type: news
Tumour vanishes in all 12 rectal cancer patients in rare medical trial result
Besides their tumours disappearing completely, none of the participants reported any severe side-effects either, says the research paper published in the New England Journal of Medicine recently. The patients underwent a series of medical exams -- physical, endoscopy, bioscopy, PET scans and MRI scans -- and none of the reports showed a tumour. (Source: The Economic Times)
Source: The Economic Times - June 8, 2022 Category: Consumer Health News Source Type: news
---
Treatment with the immunotherapy dostarlimab showed promising results in a small trial of more than a dozen rectal cancer patients, according to new research, but further study is needed and it is too early to call it a cure. CNN's Erin Burnett speaks to Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center. (Source: CNN.com - Health)
Source: CNN.com - Health - June 7, 2022 Category: Consumer Health News Source Type: news
Sanoff offers perspective on a promising rectal cancer study in the New England Journal of Medicine
UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on the evolving treatment of rectal cancer. She offers prospects for future treatment of the disease in light of encouraging findings from a study published in the journal that found the immunotherapy drug dostarlimab was especially effective in a phase II clinical trial of a dozen patients with a subtype of rectal cancer. (Source: World Pharma News)
Source: World Pharma News - June 7, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
In Small Study, New Treatment Brings Remission of Rectal Cancer in All Patients
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 6, 2022 Category: Cancer & Oncology Tags: Family Medicine, Oncology, Pharmacy, Research, News, Source Type: news
In Small Study, New Treatment Brings Remission of Rectal Cancer in All Patients
MONDAY, June 6, 2022 -- A small study delivers startling results on the power of a new immunotherapy treatment against rectal cancer: The drug triggered remission in all the patients who got it.
All of them had mismatch repair-deficient (MMRd)... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 6, 2022 Category: General Medicine Source Type: news
Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition
(MedPage Today) -- CHICAGO -- Single-agent dostarlimab (Jemperli) led to complete responses in 100% of a small group of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, allowing them to avoid surgery, chemotherapy... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 6, 2022 Category: Gastroenterology Source Type: news
